Activated immune-cell therapies

Natural Killer (NK) cells are highly specialized lymphocytes of the innate immune system that act as the body's first line of defense against viral infections and developing cancers. Unlike T-cells, NK cells possess the unique ability to immediately identify and destroy abnormal cells without requiring any prior exposure or antigen presentation.

However, aging, stress, chronic illness, and immunosuppressive tumor factors drastically decrease NK cell count and activity. Activated NK Cell Therapy harvests a small sample of the patient's blood, expands the NK cells in culture, restores their cytotoxic activity, and reinfuses them to reinforce this arm of the immune response.

A small, standard sample of 25 ml of venous blood is collected from the patient via simple venipuncture. In a certified cell-processing laboratory, the NK cells are isolated and cultured for about 14 days. Using defined nutrient media and cytokine stimulation (including IL-2 and IL-15), the starting population is expanded up to several thousand-fold, increasing both cell number and cytotoxicity.

The resulting activated NK cells are suspended in sterile saline and returned to the patient via a gentle intravenous drip over a 30-minute period. A complete standard course consists of 6 infusions administered bi-weekly on an outpatient basis. Side effects are minor, occasionally limited to a self-limiting mild fever or fatigue that completely resolves within a day.

Active NK/NKT/gamma-delta T Cell Therapy cultures and activates three classes of lymphocytes together: Natural Killer (NK) cells, Natural Killer T (NKT) cells, and gamma-delta T-cells. By engaging both the rapid, non-specific response of innate immunity and the more targeted, durable response of adaptive immunity, the approach aims to address complex, treatment-resistant solid tumors through several pathways at once and to reduce the likelihood of recurrence.

The process begins with a standard, low-volume venous blood draw (approximately 25 ml). In a certified clinical laboratory, the NK, NKT, and gamma-delta T-cells are isolated and cultured together for 14 days using specialized cultivation technologies to ensure a perfectly balanced, highly active cell population.

The cells are returned to the patient via a standard intravenous drip on an outpatient basis, requiring no hospitalization. A standard course consists of 6 infusions every two weeks. Because the therapy uses the patient's own cells, serious side effects are uncommon; some patients experience a brief mild fever or chills that resolve within about 24 hours.

Second Generation GcMAF (Gc Protein-derived Macrophage Activating Factor) is an investigational biological preparation proposed as a macrophage-activating immunotherapy. GcMAF is a naturally occurring protein derived from vitamin D-binding protein that has been described as a signal for macrophage activation. Its clinical benefit in cancer or neurodevelopmental conditions has not been established in rigorous trials, and it remains scientifically contested; the summary below describes the proposed rationale rather than proven effects.

Some cancer cells and viral infections secrete an enzyme called nagalase, which has been reported to reduce endogenous GcMAF activity. The proposed rationale is that administering purified GcMAF bypasses this effect and helps activate macrophages; investigators have also explored possible roles in microglia regulation in Autism Spectrum Disorder (ASD). These mechanisms remain hypotheses under investigation.

Second Generation GcMAF is prepared in specialized laboratories using purification processes from milk proteins or serum, intended to yield a concentrated and stable formulation.

The therapy is administered via simple, virtually painless subcutaneous (SC) or intramuscular (IM) injections, typically using a fine, single-use sterile syringe.

• For Oncology Support: A standard high-dose protocol consists of 0.5 ml injections (1500 ng) 2 to 3 times per week, often continued as a 6-month course of 48 doses, with regular monitoring of tumor markers and nagalase levels.
• For Autism Spectrum Support (ASD): A lower-dose protocol is used, typically starting at 0.1 ml in the first week and adjusting toward a maintenance dose of 0.25 ml twice weekly. Some small studies have reported behavioral or cognitive changes within the first months, but benefit is not established.

In reported use the therapy has been well tolerated; a small minority of patients (roughly 1 in 100) may experience a self-limiting low-grade fever or a transient skin reaction at the injection site.

Mixed Bacterial Vaccine Therapy (conventionally known as Coley's Toxins) is an established form of cancer immunotherapy that uses a sterile, inactivated mixture of gram-positive Streptococcus pyogenes and gram-negative Serratia marcescens bacteria. By mimicking features of a systemic bacterial infection without causing active disease, the therapy is intended to act as a strong immunological stimulus, reactivating suppressed immune cells within solid tumors and prompting a systemic anti-tumor response.

Lymphokine-Activated Killer (LAK) cell therapy is an established cellular immunotherapy that harvests, multiplies, and activates the patient's own cytotoxic T-lymphocytes and natural killer cells outside the body. By culturing these cells with high concentrations of immune-stimulating cytokines, they acquire broad cytotoxic activity before being reinfused. This non-specific mechanism is of particular interest for targeting circulating tumor cells, micrometastases, and residual cancer cells that can persist after surgery or chemotherapy.

The therapy begins with a standard 25 ml venous blood draw. Under strict, sterile cleanroom conditions, the lymphocytes are isolated and cultured in a customized medium containing high-dose cytokines for approximately 14 days. This process expands a small starting population into billions of activated lymphocytes.

Once cultivation is complete, the cells are suspended in sterile saline and returned to the patient via a standard intravenous drip over approximately 30 to 60 minutes. A standard round consists of 6 infusions spaced two weeks apart. Because the treatment uses the patient's own immune cells, serious side effects are uncommon; some patients experience transient mild shivering or a low-grade fever (37°C–38°C) within a few hours of the infusion, which usually subsides within 24 hours.